PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.

摘要: // Francois Bertucci 1, 2, 3 , Pascal Finetti 1 Cecile Colpaert 4 Emilie Mamessier Maxime Parizel Luc Dirix 5 Patrice Viens Daniel Birnbaum Steven van Laere Departement d’Oncologie Moleculaire, “Equipe Labellisee Ligue Contre le Cancer”, Centre de Recherche en Cancerologie Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Marseille, France 2 Medicale, CRCM, Faculte Medecine, Aix-Marseille Universite, Department of Pathology, GZA Hospitals Sint-Augustinus, Antwerp, Belgium Center for Oncological Research (CORE), Faculty Medicine and Health Sciences, University Antwerp Correspondence to: Bertucci, e-mail: bertuccif@ipc.unicancer.fr Keywords: chemotherapy, inflammatory breast cancer, immune response, PDL1, survival Received: January 23, 2015      Accepted: March Published: April 11, 2015 ABSTRACT We retrospectively analyzed PDL1 mRNA expression in 306 cancer samples, including 112 samples an aggressive form, (IBC). was heterogeneous, but higher IBC than non-IBC. Compared to normal overexpressed 38% IBC. In IBC, overexpression associated with estrogen receptor-negative status, basal ERBB2-enriched subtypes, clinico-biological signs anti-tumor T-cell cytotoxic response. better pathological response independently histo-clinical variables predictive gene signatures. No correlation found metastasis-free overall specific survivals. conclusion, correlated chemotherapy. This seemingly counterintuitive between immunosuppressive molecule improved therapeutic may be resolved if is viewed as a surrogate marker strong antitumor among patients treated immunogenic such patients, inhibition could protect activated T-cells or reactivate inhibited improve the notably when